Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-02

AUTHORS

Carlos Castaneda, Kellen L. Meadows, Roxanne Truax, Michael A. Morse, Scott H. Kaufmann, William P. Petros, Yali Zhu, Paul Statkevich, David L. Cutler, Herbert I. Hurwitz

ABSTRACT

PURPOSE: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. METHODS: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Dose-limiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336- induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. RESULTS: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. CONCLUSION: The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study. More... »

PAGES

455-463

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5

DOI

http://dx.doi.org/10.1007/s00280-010-1488-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031662375

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20972873


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alkyl and Aryl Transferases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lamin Type A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mouth Mucosa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nuclear Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Precursors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Instituto Nacional de Enfermedades Neopl\u00e1sicas", 
          "id": "https://www.grid.ac/institutes/grid.419177.d", 
          "name": [
            "Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castaneda", 
        "givenName": "Carlos", 
        "id": "sg:person.01030612671.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030612671.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meadows", 
        "givenName": "Kellen L.", 
        "id": "sg:person.014460031617.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014460031617.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Truax", 
        "givenName": "Roxanne", 
        "id": "sg:person.01133626763.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133626763.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morse", 
        "givenName": "Michael A.", 
        "id": "sg:person.013700705377.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mayo Clinic", 
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Mayo Clinic, 55905, Rochester, Minnesota, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaufmann", 
        "givenName": "Scott H.", 
        "id": "sg:person.01342126052.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342126052.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "West Virginia University", 
          "id": "https://www.grid.ac/institutes/grid.268154.c", 
          "name": [
            "Mary Babb Randolph Cancer Center, West Virginia University, 26506, Morgantown, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petros", 
        "givenName": "William P.", 
        "id": "sg:person.0610003000.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610003000.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Yali", 
        "id": "sg:person.01357562202.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357562202.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Statkevich", 
        "givenName": "Paul", 
        "id": "sg:person.01254454060.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254454060.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cutler", 
        "givenName": "David L.", 
        "id": "sg:person.0673106361.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673106361.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, 27710, Durham, North Carolina, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hurwitz", 
        "givenName": "Herbert I.", 
        "id": "sg:person.01242177577.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1073/pnas.0403413101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003416326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.seminoncol.2003.12.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004296390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.270.11.6221", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004876600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m503763200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005457814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m503763200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005457814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.22.14459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009618696"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1262", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014070179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.22.14093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015163692"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v97.5.1404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015234213"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22901", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017566383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-03-0412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019198461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0304-419x(97)00011-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022401551"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025114095", 
          "https://doi.org/10.1038/sj.onc.1202175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025114095", 
          "https://doi.org/10.1038/sj.onc.1202175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026802485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026802485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.270.43.25827", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031151964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0092-8674(90)90294-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032239893"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-008-0536-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033310854", 
          "https://doi.org/10.1007/s00277-008-0536-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-2635", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033311674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2005.03.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034672756"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.89.14.6403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036302734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.25.15591", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038597429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e318187dd57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045077743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e318187dd57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045077743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/coc.0b013e318187dd57", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045077743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00379-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046295840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(02)00379-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046295840"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.272.15.10232", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051296996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.4243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052654075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v97.5.1399", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052670192"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m003469200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052870195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1201656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052887834", 
          "https://doi.org/10.1038/sj.onc.1201656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1201656", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052887834", 
          "https://doi.org/10.1038/sj.onc.1201656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/tx000138v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056296385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/tx000138v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056296385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008313232381", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074623638", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074660237", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.4.1167", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074754841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074813249", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074829589", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076575034", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1460-2075.1991.tb04979.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077431375"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079010052", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083344559", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-02", 
    "datePublishedReg": "2011-02-01", 
    "description": "PURPOSE: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted.\nMETHODS: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Dose-limiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336- induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa.\nRESULTS: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses.\nCONCLUSION: The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-010-1488-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "67"
      }
    ], 
    "name": "Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors", 
    "pagination": "455-463", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "96d56db3293bcbbccd2d2f6ddbdc772c27602438fa7bc47f099432cd8989a5ac"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20972873"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-010-1488-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031662375"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-010-1488-5", 
      "https://app.dimensions.ai/details/publication/pub.1031662375"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-010-1488-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1488-5'


 

This table displays all metadata directly associated to this object as RDF triples.

330 TRIPLES      21 PREDICATES      86 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-010-1488-5 schema:about N0b0a82c98ce44c549c19e82e0ff5fda3
2 N2400fcd17be84e32b07e127eaaf47a53
3 N752cc2cffd544abbb161d9b82b6ef089
4 N84aae5fdd02e48f88cb9fc2f4a6d2c07
5 N89f5f206e0ec4aaab528fe8f563f7443
6 N8a1738c6b1374247a41ca5cb197c5280
7 N8a5f759ddb8b43b48428589a637455a1
8 N94193c510bb74935b9b9ab941aa7290b
9 Na9f4ca71f81d4b2cb5ff880f56c75ea0
10 Naf2512e05ef9427d837a1d932eede24b
11 Nb330b2093b6e4e0ea17c797fc63b3c52
12 Nb37a90130bf1438ba32c8d7dad523401
13 Nb7ffa067c43e4f4c9480708af0b26061
14 Nbf6016abed8b44f5aa2a938b40932760
15 Nc0fe72ea8596454694ac3be8f51848eb
16 Nd901e3e5b3f44739a67e8119a3fe99f0
17 Nd9a24debc0204128bdeb0860c370a323
18 Ne64bf21e19704186abed2c2feb819170
19 Nff38f4e8e1b34ee9a4609014961b8520
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N9847435b6b2044bea46d85c96a00e44e
23 schema:citation sg:pub.10.1007/s00277-008-0536-2
24 sg:pub.10.1038/sj.onc.1201656
25 sg:pub.10.1038/sj.onc.1202175
26 https://app.dimensions.ai/details/publication/pub.1074623638
27 https://app.dimensions.ai/details/publication/pub.1074660237
28 https://app.dimensions.ai/details/publication/pub.1074813249
29 https://app.dimensions.ai/details/publication/pub.1074829589
30 https://app.dimensions.ai/details/publication/pub.1076575034
31 https://app.dimensions.ai/details/publication/pub.1079010052
32 https://app.dimensions.ai/details/publication/pub.1083344559
33 https://doi.org/10.1002/cncr.21188
34 https://doi.org/10.1002/cncr.22901
35 https://doi.org/10.1002/j.1460-2075.1991.tb04979.x
36 https://doi.org/10.1016/0092-8674(90)90294-o
37 https://doi.org/10.1016/j.ccr.2005.03.024
38 https://doi.org/10.1016/s0304-419x(97)00011-5
39 https://doi.org/10.1016/s0959-8049(02)00379-9
40 https://doi.org/10.1021/tx000138v
41 https://doi.org/10.1023/a:1008313232381
42 https://doi.org/10.1053/j.seminoncol.2003.12.012
43 https://doi.org/10.1073/pnas.0403413101
44 https://doi.org/10.1073/pnas.89.14.6403
45 https://doi.org/10.1074/jbc.270.11.6221
46 https://doi.org/10.1074/jbc.270.43.25827
47 https://doi.org/10.1074/jbc.272.15.10232
48 https://doi.org/10.1074/jbc.272.22.14093
49 https://doi.org/10.1074/jbc.272.22.14459
50 https://doi.org/10.1074/jbc.272.25.15591
51 https://doi.org/10.1074/jbc.m003469200
52 https://doi.org/10.1074/jbc.m503763200
53 https://doi.org/10.1097/coc.0b013e318187dd57
54 https://doi.org/10.1158/0008-5472.can-05-2635
55 https://doi.org/10.1158/1078-0432.ccr-03-0412
56 https://doi.org/10.1158/1078-0432.ccr-06-1262
57 https://doi.org/10.1182/blood.v97.5.1399
58 https://doi.org/10.1182/blood.v97.5.1404
59 https://doi.org/10.1200/jco.2001.19.4.1167
60 https://doi.org/10.1200/jco.2006.09.4243
61 schema:datePublished 2011-02
62 schema:datePublishedReg 2011-02-01
63 schema:description PURPOSE: This phase I study was performed to determine the safety profile, maximum tolerated dose (MTD) and biological activity of lonafarnib (SCH 66336). Single-dose and multi-dose pharmacokinetics were conducted. METHODS: Twenty-one patients with advanced solid tumors were enrolled. Each patient received single-dose administration on day 1, cycle 1 then switched to a twice daily (BID) dosing regimen on days 2-14 of a 28-day cycle; subsequent cycles continued BID dosing on days 1-14. Dose-limiting toxicity (DLT) was assessed during the cycle one; toxicity evaluation was closely monitored throughout the treatment. Radiographic scans were completed to assess tumor response. Blood and urine pharmacokinetics were evaluated on days 1 and 14 in cycle 1. SCH 66336- induced farnesylation inhibition was assessed via conversion of prelamin A to lamin in buccal mucosa. RESULTS: DLT and most common adverse events were diarrhea, fatigue, nausea and anorexia. No grade 3 or 4 hematological toxicities were observed. Nineteen of 21 patients were evaluable for response; short-term stable disease was observed in 5 patients. SCH 66336 systemic exposure increased with dose; however, drug accumulation was higher than projected. Renal excretion of parent drug was negligible. Farnesyl transferase inhibition was detected at the 200 and 300 mg BID doses. CONCLUSION: The MTD and recommended phase II dose is 200 mg BID on days 1-14 of a 28-day dosing regimen. The plasma concentration profile suggests the pharmacokinetics of SCH 66336 is dose and time dependent. Farnesyl transferase target inhibition was observed at doses of lonafarnib recommended for further study.
64 schema:genre research_article
65 schema:inLanguage en
66 schema:isAccessibleForFree false
67 schema:isPartOf N3c4daaeb46564e3c816aee5c2d6959e4
68 Nf9ce74b44cb64039aaa9c04027a0128b
69 sg:journal.1088364
70 schema:name Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors
71 schema:pagination 455-463
72 schema:productId N00f24687cfee403c8689beadf55e4e92
73 N570b122c03e54a6ea47d37c52513795a
74 N6b3cd5f8f62d4278b2d83e59f99f8a06
75 N7e8d648ccf5545d39230b1f2055cf407
76 N7e90222125c240bb999361cbb89a905e
77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031662375
78 https://doi.org/10.1007/s00280-010-1488-5
79 schema:sdDatePublished 2019-04-11T00:16
80 schema:sdLicense https://scigraph.springernature.com/explorer/license/
81 schema:sdPublisher Nbde2fc0ed5b34548958f33430e7918ca
82 schema:url http://link.springer.com/10.1007%2Fs00280-010-1488-5
83 sgo:license sg:explorer/license/
84 sgo:sdDataset articles
85 rdf:type schema:ScholarlyArticle
86 N00f24687cfee403c8689beadf55e4e92 schema:name doi
87 schema:value 10.1007/s00280-010-1488-5
88 rdf:type schema:PropertyValue
89 N0b0a82c98ce44c549c19e82e0ff5fda3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Mouth Mucosa
91 rdf:type schema:DefinedTerm
92 N1d5b3b7603a545e8b522b9c6a0226c2e rdf:first sg:person.01357562202.28
93 rdf:rest Nba5b80215e4b4051a961abd9b8ba9529
94 N23e4efbf4d014fbca03dc9ce2707bb53 rdf:first sg:person.0610003000.44
95 rdf:rest N1d5b3b7603a545e8b522b9c6a0226c2e
96 N2400fcd17be84e32b07e127eaaf47a53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Lamin Type A
98 rdf:type schema:DefinedTerm
99 N27c03b8497ee492caada7afe77f1ec9b rdf:first sg:person.013700705377.06
100 rdf:rest Nb65fb349f233493989cd0c1f9ef015b7
101 N3c4daaeb46564e3c816aee5c2d6959e4 schema:issueNumber 2
102 rdf:type schema:PublicationIssue
103 N4f20e93f6b6642ebaba3860f1f0676f9 rdf:first sg:person.014460031617.65
104 rdf:rest Ne9ffa24b26ef48cfb6f24e874c2b609b
105 N570b122c03e54a6ea47d37c52513795a schema:name dimensions_id
106 schema:value pub.1031662375
107 rdf:type schema:PropertyValue
108 N6b3cd5f8f62d4278b2d83e59f99f8a06 schema:name pubmed_id
109 schema:value 20972873
110 rdf:type schema:PropertyValue
111 N752cc2cffd544abbb161d9b82b6ef089 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Pyridines
113 rdf:type schema:DefinedTerm
114 N7e8d648ccf5545d39230b1f2055cf407 schema:name nlm_unique_id
115 schema:value 7806519
116 rdf:type schema:PropertyValue
117 N7e90222125c240bb999361cbb89a905e schema:name readcube_id
118 schema:value 96d56db3293bcbbccd2d2f6ddbdc772c27602438fa7bc47f099432cd8989a5ac
119 rdf:type schema:PropertyValue
120 N7fc7b35963e5482d811175501f783b87 rdf:first sg:person.01242177577.68
121 rdf:rest rdf:nil
122 N84aae5fdd02e48f88cb9fc2f4a6d2c07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Maximum Tolerated Dose
124 rdf:type schema:DefinedTerm
125 N89f5f206e0ec4aaab528fe8f563f7443 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Neoplasms
127 rdf:type schema:DefinedTerm
128 N8a1738c6b1374247a41ca5cb197c5280 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Protein Precursors
130 rdf:type schema:DefinedTerm
131 N8a5f759ddb8b43b48428589a637455a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Nuclear Proteins
133 rdf:type schema:DefinedTerm
134 N94193c510bb74935b9b9ab941aa7290b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Area Under Curve
136 rdf:type schema:DefinedTerm
137 N9847435b6b2044bea46d85c96a00e44e rdf:first sg:person.01030612671.69
138 rdf:rest N4f20e93f6b6642ebaba3860f1f0676f9
139 Na9f4ca71f81d4b2cb5ff880f56c75ea0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Piperidines
141 rdf:type schema:DefinedTerm
142 Naf2512e05ef9427d837a1d932eede24b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Enzyme Inhibitors
144 rdf:type schema:DefinedTerm
145 Nb330b2093b6e4e0ea17c797fc63b3c52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Antineoplastic Agents
147 rdf:type schema:DefinedTerm
148 Nb37a90130bf1438ba32c8d7dad523401 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Humans
150 rdf:type schema:DefinedTerm
151 Nb65fb349f233493989cd0c1f9ef015b7 rdf:first sg:person.01342126052.27
152 rdf:rest N23e4efbf4d014fbca03dc9ce2707bb53
153 Nb7ffa067c43e4f4c9480708af0b26061 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Aged
155 rdf:type schema:DefinedTerm
156 Nba5b80215e4b4051a961abd9b8ba9529 rdf:first sg:person.01254454060.82
157 rdf:rest Nf7ca99457dce411d813f6a465b7e67fe
158 Nbde2fc0ed5b34548958f33430e7918ca schema:name Springer Nature - SN SciGraph project
159 rdf:type schema:Organization
160 Nbf6016abed8b44f5aa2a938b40932760 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Male
162 rdf:type schema:DefinedTerm
163 Nc0fe72ea8596454694ac3be8f51848eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Alkyl and Aryl Transferases
165 rdf:type schema:DefinedTerm
166 Nd901e3e5b3f44739a67e8119a3fe99f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Middle Aged
168 rdf:type schema:DefinedTerm
169 Nd9a24debc0204128bdeb0860c370a323 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 Ne64bf21e19704186abed2c2feb819170 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Adult
174 rdf:type schema:DefinedTerm
175 Ne9ffa24b26ef48cfb6f24e874c2b609b rdf:first sg:person.01133626763.37
176 rdf:rest N27c03b8497ee492caada7afe77f1ec9b
177 Nf7ca99457dce411d813f6a465b7e67fe rdf:first sg:person.0673106361.44
178 rdf:rest N7fc7b35963e5482d811175501f783b87
179 Nf9ce74b44cb64039aaa9c04027a0128b schema:volumeNumber 67
180 rdf:type schema:PublicationVolume
181 Nff38f4e8e1b34ee9a4609014961b8520 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Treatment Outcome
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1088364 schema:issn 0344-5704
191 1432-0843
192 schema:name Cancer Chemotherapy and Pharmacology
193 rdf:type schema:Periodical
194 sg:person.01030612671.69 schema:affiliation https://www.grid.ac/institutes/grid.419177.d
195 schema:familyName Castaneda
196 schema:givenName Carlos
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030612671.69
198 rdf:type schema:Person
199 sg:person.01133626763.37 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
200 schema:familyName Truax
201 schema:givenName Roxanne
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133626763.37
203 rdf:type schema:Person
204 sg:person.01242177577.68 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
205 schema:familyName Hurwitz
206 schema:givenName Herbert I.
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242177577.68
208 rdf:type schema:Person
209 sg:person.01254454060.82 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
210 schema:familyName Statkevich
211 schema:givenName Paul
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254454060.82
213 rdf:type schema:Person
214 sg:person.01342126052.27 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
215 schema:familyName Kaufmann
216 schema:givenName Scott H.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342126052.27
218 rdf:type schema:Person
219 sg:person.01357562202.28 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
220 schema:familyName Zhu
221 schema:givenName Yali
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357562202.28
223 rdf:type schema:Person
224 sg:person.013700705377.06 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
225 schema:familyName Morse
226 schema:givenName Michael A.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013700705377.06
228 rdf:type schema:Person
229 sg:person.014460031617.65 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
230 schema:familyName Meadows
231 schema:givenName Kellen L.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014460031617.65
233 rdf:type schema:Person
234 sg:person.0610003000.44 schema:affiliation https://www.grid.ac/institutes/grid.268154.c
235 schema:familyName Petros
236 schema:givenName William P.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610003000.44
238 rdf:type schema:Person
239 sg:person.0673106361.44 schema:affiliation https://www.grid.ac/institutes/grid.417993.1
240 schema:familyName Cutler
241 schema:givenName David L.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673106361.44
243 rdf:type schema:Person
244 sg:pub.10.1007/s00277-008-0536-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033310854
245 https://doi.org/10.1007/s00277-008-0536-2
246 rdf:type schema:CreativeWork
247 sg:pub.10.1038/sj.onc.1201656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052887834
248 https://doi.org/10.1038/sj.onc.1201656
249 rdf:type schema:CreativeWork
250 sg:pub.10.1038/sj.onc.1202175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025114095
251 https://doi.org/10.1038/sj.onc.1202175
252 rdf:type schema:CreativeWork
253 https://app.dimensions.ai/details/publication/pub.1074623638 schema:CreativeWork
254 https://app.dimensions.ai/details/publication/pub.1074660237 schema:CreativeWork
255 https://app.dimensions.ai/details/publication/pub.1074813249 schema:CreativeWork
256 https://app.dimensions.ai/details/publication/pub.1074829589 schema:CreativeWork
257 https://app.dimensions.ai/details/publication/pub.1076575034 schema:CreativeWork
258 https://app.dimensions.ai/details/publication/pub.1079010052 schema:CreativeWork
259 https://app.dimensions.ai/details/publication/pub.1083344559 schema:CreativeWork
260 https://doi.org/10.1002/cncr.21188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026802485
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1002/cncr.22901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017566383
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1002/j.1460-2075.1991.tb04979.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1077431375
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1016/0092-8674(90)90294-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1032239893
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1016/j.ccr.2005.03.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034672756
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1016/s0304-419x(97)00011-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022401551
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1016/s0959-8049(02)00379-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046295840
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1021/tx000138v schema:sameAs https://app.dimensions.ai/details/publication/pub.1056296385
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1023/a:1008313232381 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303084
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1053/j.seminoncol.2003.12.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004296390
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1073/pnas.0403413101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003416326
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1073/pnas.89.14.6403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036302734
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1074/jbc.270.11.6221 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004876600
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1074/jbc.270.43.25827 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031151964
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1074/jbc.272.15.10232 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051296996
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1074/jbc.272.22.14093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015163692
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1074/jbc.272.22.14459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009618696
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1074/jbc.272.25.15591 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038597429
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1074/jbc.m003469200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052870195
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1074/jbc.m503763200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005457814
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1097/coc.0b013e318187dd57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045077743
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1158/0008-5472.can-05-2635 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033311674
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1158/1078-0432.ccr-03-0412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019198461
305 rdf:type schema:CreativeWork
306 https://doi.org/10.1158/1078-0432.ccr-06-1262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014070179
307 rdf:type schema:CreativeWork
308 https://doi.org/10.1182/blood.v97.5.1399 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052670192
309 rdf:type schema:CreativeWork
310 https://doi.org/10.1182/blood.v97.5.1404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015234213
311 rdf:type schema:CreativeWork
312 https://doi.org/10.1200/jco.2001.19.4.1167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074754841
313 rdf:type schema:CreativeWork
314 https://doi.org/10.1200/jco.2006.09.4243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052654075
315 rdf:type schema:CreativeWork
316 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
317 schema:name Duke University Medical Center, 27710, Durham, North Carolina, USA
318 rdf:type schema:Organization
319 https://www.grid.ac/institutes/grid.268154.c schema:alternateName West Virginia University
320 schema:name Mary Babb Randolph Cancer Center, West Virginia University, 26506, Morgantown, WV, USA
321 rdf:type schema:Organization
322 https://www.grid.ac/institutes/grid.417993.1 schema:alternateName MSD (United States)
323 schema:name Schering-Plough Research Institute, 07033, Kenilworth, New Jersey, USA
324 rdf:type schema:Organization
325 https://www.grid.ac/institutes/grid.419177.d schema:alternateName Instituto Nacional de Enfermedades Neoplásicas
326 schema:name Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
327 rdf:type schema:Organization
328 https://www.grid.ac/institutes/grid.66875.3a schema:alternateName Mayo Clinic
329 schema:name Mayo Clinic, 55905, Rochester, Minnesota, USA
330 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...